The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Patterns of chemotherapy (CT) use in a population-based US-wide cohort of patients (pts) with metastatic pancreatic cancer (MPC).
Thomas Adam Abrams
Research Funding - Celgene
Gary Meyer
Employment or Leadership Position - IntrinsiQ
Julie Moloney
Employment or Leadership Position - IntrinsiQ
Jeffrey A. Meyerhardt
No relevant relationships to disclose
Brian M. Wolpin
No relevant relationships to disclose
Deborah Schrag
No relevant relationships to disclose
Charles S. Fuchs
Consultant or Advisory Role - Amgen; Celgene; Genentech; Lilly; Metamark Genetics; Momenta Pharmaceuticals; Sanofi ; Takeda; Vertex